tirzepatide breastfeeding safety and Breastfeeding: What Moms Need to Know Tirzepatide no longer contraindicated during

Scenario 4: body recomposition (athletes and active individuals) Starting point: physically active, moderate excess weight, primary goal is improving body composition and performance

Some patients gain muscle while losing body fat, especially when strength training is part of their routine

Clinical data from the SURMOUNT trials showed that approximately 25 to 30 percent of weight lost on tirzepatide comes from lean mass rather than fat

STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) primary clinical trial for semaglutide 2.4 mg (Wegovy), source for the cross-drug diarrhea-rate comparison

Once a medication is initiated, patients should be assessed at regular intervals (preferably at least monthly for the first three months) to assess its efficacy, which is typically defined as 5% total body weight loss at three months, and to assess its safety

However, due to its dual mechanism, some patients might experience these side effects more intensely